SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors

Kurt Zimmermann(Bristol-Myers Squibb (United States)), Dolatrai M. Vyas(Bristol-Myers Squibb (United States)), Zheng Yang(Renmin Hospital of Wuhan University), Upender Velaparthi(Bristol-Myers Squibb (United States)), Xiaopeng Sang(Bristol-Myers Squibb (United States)), Marco M. Gottardis(Georgetown University), David B. Frennesson(Bristol-Myers Squibb (United States)), Lorell Discenza(Bristol-Myers Squibb (United States)), Ricardo M. Attar(Johnson & Johnson (United States)), Sean Kim(Bristol-Myers Squibb (Germany)), Mark G. Saulnier(Bristol-Myers Squibb (United States)), Ann Greer(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Francis Y. Lee(Yale University), Joan M. Carboni(Bristol-Myers Squibb (United States)), Steven P. Seitz(Bristol-Myers Squibb (Germany)), Liqi He(Bristol-Myers Squibb (United States)), Aixin Li(University of South China), Mark D. Wittman(Bristol-Myers Squibb (United States)), Charles Struzynski(Bristol-Myers Squibb (United States)), Praveen Balimane(Bristol-Myers Squibb (United States))
Bioorganic & Medicinal Chemistry Letters
January 22, 2010
Cited by 25


Related Papers